Tag: Triphenylethylene SERM (mixed isomers)

  • Clomiphene

    Triphenylethylene SERM (mixed isomers)

    A racemic mixture of enclomiphene (anti-estrogen) and zuclomiphene (estrogen agonist); the prototype ovulation-inducing agent.

    Abstract

    Clomiphene (2-[4-[(E/Z)-2-chloro-1,2-diphenylvinyl]phenoxy]-N,N-diethylethanamine; CAS 911-45-5; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Merrell and approved by the FDA in 1967 under the trade name Clomid. The compound is sold as a racemic mixture of approximately 38 percent zuclomiphene ((Z)-isomer, an ER agonist) and 62 percent enclomiphene ((E)-isomer, an ER antagonist). The therapeutic effect in ovulation induction is driven primarily by enclomiphene-mediated antagonism of hypothalamic ER, releasing the negative feedback on GnRH and consequently increasing pituitary FSH and LH; the resulting follicular development drives ovulation. The zuclomiphene component is approximately 5-fold longer half-life than enclomiphene (zuclomiphene t1/2 approximately 30 days, enclomiphene t1/2 approximately 30 hours), causing the agonist component to dominate at later cycles and produce some unwanted estrogen-like effects (cervical mucus changes, antiestrogen rebound). Approved for ovulation induction in anovulatory women. Off-label use in male hypogonadism (induces endogenous testosterone via the same FSH/LH route) is common. Used as the canonical triphenylethylene SERM with HPG-stimulating activity.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.